SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Silexion Therapeutics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.15+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $105.17K
- P/E (TTM)
- 0.0
- Dividend yield
- –
Share price
−$35.0470 (−99.57%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $105.17K
- P/E ratio
- 0.0
- Price to sales
- –
- Price to book
- 2.39
- Dividend yield
- –
- Free cash flow yield
- -11821.42%
Fundamentals
- Net income
- -$13.96M
- EPS, diluted
- $8.96
- Free cash flow
- -$12.43M
- Book value per share
- $0.06
- Diluted shares
- 1M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$14.13M
Net income
-$13.96M
EPS, diluted
–
Free cash flow
-$12.43M
Reported periodTrailing twelve months